PRIVATE-LABEL OTC DIAGNOSTIC TEST SALES FELL 5%
This article was originally published in The Gray Sheet
Executive Summary
PRIVATE-LABEL OTC DIAGNOSTIC TEST SALES FELL 5% in the 12 months through June 1994 versus the same period in 1993, according to a report on home diagnostics sales compiled by Information Resources, Inc. subsidiary Towne-Oller. For the 12-month period, private-label diagnostic tests held only a 2.1% dollar share of the $660.6 mil. home diagnostics market, a decline from 2.6% the previous year.
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.